Mollyycolllinss Categories Finance
7 days
30 days
All time
Recent
Popular
When people asked to reallocate funds from Police in Hamilton in June 2020, this happened. My view, the issue of resisting changes to police budget is far more systemic than people think. They invested in fighting it. @samnabi @ReallocateW @OfAcb @570NEWS
Stephen Harper invested in prisons. Corruption, collusion and bid rigging involved Richard Bird of Enbridge. He owns Bird Construction Inc. He builds court houses, prisons, opp and RCMP detachments.
Enbridge has been fiscally donating to police for a long time.
Police and fire department as first responders have judicial power to decide when to call the MNR spills action centre when accidents happen. I know this from a spill I witnessed in the Humber River. Police and oil are too close and conflicts exist.
The Ontario Ministry of the Environment’s failure to charge Imperial Oil signals that “the minister’s promise to police industry and enforce existing environmental laws is an empty one.” - @ecojustice_ca scientist Elaine MacDonald https://t.co/p2qBSrSlLl #onpoli
Stephen Harper invested in prisons. Corruption, collusion and bid rigging involved Richard Bird of Enbridge. He owns Bird Construction Inc. He builds court houses, prisons, opp and RCMP detachments.
Enbridge has been fiscally donating to police for a long time.
Police and fire department as first responders have judicial power to decide when to call the MNR spills action centre when accidents happen. I know this from a spill I witnessed in the Humber River. Police and oil are too close and conflicts exist.
The Ontario Ministry of the Environment’s failure to charge Imperial Oil signals that “the minister’s promise to police industry and enforce existing environmental laws is an empty one.” - @ecojustice_ca scientist Elaine MacDonald https://t.co/p2qBSrSlLl #onpoli
@LaurusLabs #lauruslabs #Q3marketupdates #Q3investorpresentations
Q3fy21/20 in crs
Rev 1288/730 ,up 76%
Ebidta 433/150
PAT 273/73 ,up 274%
EPS 5.1/1.4
Generic API growth 103% yoy
ARVs up 175% yoy
Generic FDF up 47%
Custom synthesis up 63% yoy
Onco API growth 36%
Generic APIs
ARV,Anti-DM,CVS,PPIs,Onco
Commercialized 60+ products
61 DMFs filed
Generic FDF
ARV,Anti-DM,CVS,PPIs,Onco
Filed 26 ANDAs with USFDA
9 final & 8 tentative approvals
Filed 12 dossiers in Canada, 9 in EU ,8 with WHO,2 in https://t.co/Q35cgK2hvy, 2 in India
Laurus Synthesis
CDMO services for Global pharma
Steroids,hormone mftg
Speciality ingredients in Nutraceuticals,dietary,cosmetics
Commercial scale mfg,clinical phase supplies,Analytics & research
API validation plannd in Unit 5
Optalmic initiated
LSPL-API validatn planned
Revenue breakup in crs
Q3fy21/20
Generic API 731/360
Generic FDF 430/292
Synthesis 127/78
Generic API
ARV 568/214
Onco 64/47
Other 99/99
Generic FDF 430/292
Entered in longterm partnership with leading generic player in EU for contract mfg
Synthesis CDMO 127/78 crs
Synthesis CDMO
Revenue from custom synthesis, strong growth 63% yoy
Total active projects in CDMO stood at 49 in Q3
Partnered Large global pharma & mid ,small biotech companies
Commercial supplies ongoing for 4 products
Q3fy21/20 in crs
Rev 1288/730 ,up 76%
Ebidta 433/150
PAT 273/73 ,up 274%
EPS 5.1/1.4
Generic API growth 103% yoy
ARVs up 175% yoy
Generic FDF up 47%
Custom synthesis up 63% yoy
Onco API growth 36%
Generic APIs
ARV,Anti-DM,CVS,PPIs,Onco
Commercialized 60+ products
61 DMFs filed
Generic FDF
ARV,Anti-DM,CVS,PPIs,Onco
Filed 26 ANDAs with USFDA
9 final & 8 tentative approvals
Filed 12 dossiers in Canada, 9 in EU ,8 with WHO,2 in https://t.co/Q35cgK2hvy, 2 in India
Laurus Synthesis
CDMO services for Global pharma
Steroids,hormone mftg
Speciality ingredients in Nutraceuticals,dietary,cosmetics
Commercial scale mfg,clinical phase supplies,Analytics & research
API validation plannd in Unit 5
Optalmic initiated
LSPL-API validatn planned
Revenue breakup in crs
Q3fy21/20
Generic API 731/360
Generic FDF 430/292
Synthesis 127/78
Generic API
ARV 568/214
Onco 64/47
Other 99/99
Generic FDF 430/292
Entered in longterm partnership with leading generic player in EU for contract mfg
Synthesis CDMO 127/78 crs
Synthesis CDMO
Revenue from custom synthesis, strong growth 63% yoy
Total active projects in CDMO stood at 49 in Q3
Partnered Large global pharma & mid ,small biotech companies
Commercial supplies ongoing for 4 products
Different type of vaccine being developed at Scottish factory of a French company - an “inactivated whole virus” - UK task force secured 60m dose preorder in July for €470m with options for 130m more 2022-25, invested in factory. EU finalised first order of 30m this month.
Basically the Government through @katebingham acted like a venture capital fund, funding many vaccine candidates, expensively, across different types of tech, with companies from different countries (at time of some scepticism that a working vaccine could be produced so quickly)
Though despite the fact French Valneva had been funded for its vaccines in general in 2018 by EU’s investment bank, UK funding guaranteed its production in UK (speculative VC style investment) - similarly UK signed deal with Pfizer for German developed/ funded Biontech vaccine
UK approach explicitly focussed on speed (and boosting poor UK vaccine supply chain), at expense of cost. cost of individual batches, and cost of investing in spread of vaccines, not all would eventually be needed/ used...
EU focussed on lower price, & helping smaller EU nations
approach with Astra Zeneca went further - UK Govt via Matt Hancock involved in matchmaking AZ with Oxford University, funded early clinical trials that eg enabled private jets to ferry samples etc - 100m doses and pricing at cost were part of that deal struck at April wave 1 peak
It\u2019s brilliant that @ValnevaSE is starting the large-scale manufacture of its potential vaccine, creating 100 high-skilled jobs at their Livingston facility.
— Boris Johnson (@BorisJohnson) January 28, 2021
We\u2019ve secured 60m doses due to be delivered by the end of the year if it is approved for use.https://t.co/4pDUbczlVl
Basically the Government through @katebingham acted like a venture capital fund, funding many vaccine candidates, expensively, across different types of tech, with companies from different countries (at time of some scepticism that a working vaccine could be produced so quickly)
Though despite the fact French Valneva had been funded for its vaccines in general in 2018 by EU’s investment bank, UK funding guaranteed its production in UK (speculative VC style investment) - similarly UK signed deal with Pfizer for German developed/ funded Biontech vaccine
UK approach explicitly focussed on speed (and boosting poor UK vaccine supply chain), at expense of cost. cost of individual batches, and cost of investing in spread of vaccines, not all would eventually be needed/ used...
EU focussed on lower price, & helping smaller EU nations
approach with Astra Zeneca went further - UK Govt via Matt Hancock involved in matchmaking AZ with Oxford University, funded early clinical trials that eg enabled private jets to ferry samples etc - 100m doses and pricing at cost were part of that deal struck at April wave 1 peak
Did you catch our thread on the expanding reach of US company Palantir into UK public institutions? £91m+ awarded to the controversial Silicon Valley data-analytics outfit across government. Let's take a closer look at their work with the NHS...
examined the NHS contracts Palantir won under Covid19, trying to find out what aspects of our health data this private company has been given access to. But we couldn’t find out - key parts of the contracts are redacted.
At least £25.4m in contracts have been awarded to Palantir from UK Health Services. Their latest (Dec 2020) was worth up to £23m for them to continue deploying their Foundry data management platform within the NHS until
Foundry claims it can ‘source, connect, and transform’ data to ‘make operations analytical and analytics operational.’ It’s a big-data system that, in an NHS context, analyses patient data. More specifically, your
Palantir won their first NHS contract for just £1, supporting the COVID-19 datastore (Mar-June 2020); then a £1m, 4 month extension for the same work; then £908k for aiding the Test & Trace system (June-Sep
Many of their recent contracts have been awarded by the NHS and DHSC, who\u2019ve spent almost \xa325 million on Palantir products since the start of the pandemic, most recently spending \xa323 million for \u201cdata management platform services\u201d within the NHS over the next two years. pic.twitter.com/tk2Tw5yvay
— The Citizens (@allthecitizens) January 6, 2021
examined the NHS contracts Palantir won under Covid19, trying to find out what aspects of our health data this private company has been given access to. But we couldn’t find out - key parts of the contracts are redacted.
At least £25.4m in contracts have been awarded to Palantir from UK Health Services. Their latest (Dec 2020) was worth up to £23m for them to continue deploying their Foundry data management platform within the NHS until
Foundry claims it can ‘source, connect, and transform’ data to ‘make operations analytical and analytics operational.’ It’s a big-data system that, in an NHS context, analyses patient data. More specifically, your
Palantir won their first NHS contract for just £1, supporting the COVID-19 datastore (Mar-June 2020); then a £1m, 4 month extension for the same work; then £908k for aiding the Test & Trace system (June-Sep